These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32234526)

  • 1. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
    Sahu B; Narota A; Naura AS
    Eur J Pharmacol; 2020 Jun; 877():173091. PubMed ID: 32234526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two hit induced acute lung injury impairs cognitive function in mice: A potential model to study cross talk between lung and brain.
    Sahu B; Sandhir R; Naura AS
    Brain Behav Immun; 2018 Oct; 73():633-642. PubMed ID: 30026058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
    Liu W; Ren X; Wang Q; Zhang Y; Du J
    Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
    Kapoor K; Singla E; Sahu B; Naura AS
    Mol Cell Biochem; 2015 Feb; 400(1-2):153-62. PubMed ID: 25404465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
    Dharwal V; Naura AS
    Biochem Pharmacol; 2018 Apr; 150():24-34. PubMed ID: 29355504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
    Ghonim MA; Pyakurel K; Ibba SV; Al-Khami AA; Wang J; Rodriguez P; Rady HF; El-Bahrawy AH; Lammi MR; Mansy MS; Al-Ghareeb K; Ramsay A; Ochoa A; Naura AS; Boulares AH
    J Transl Med; 2015 Jul; 13():225. PubMed ID: 26169874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate prevents acute lung injury related cognitive impairment potentially via reducing inflammation.
    Wang X; Wang Y; Pan H; Yan C
    J Cardiothorac Surg; 2021 Nov; 16(1):331. PubMed ID: 34772431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
    Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
    Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
    Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
    Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
    Ahmad A; Haas De Mello A; Szczesny B; Törö G; Marcatti M; Druzhyna N; Liaudet L; Tarantini S; Salomao R; Garcia Soriano F; Szabo C
    Shock; 2020 May; 53(5):653-665. PubMed ID: 31274831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
    Sethi GS; Sharma S; Naura AS
    IUBMB Life; 2019 Jul; 71(7):1003-1013. PubMed ID: 30964965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes.
    Mustafa K; Han Y; He D; Wang Y; Niu N; Jose PA; Jiang Y; Kopp JB; Lee H; Qu P
    PLoS One; 2024; 19(2):e0295837. PubMed ID: 38335214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
    Kovács D; Vántus VB; Vámos E; Kálmán N; Schicho R; Gallyas F; Radnai B
    Oxid Med Cell Longev; 2021; 2021():7308897. PubMed ID: 34567413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
    Ahmad A; Olah G; Herndon DN; Szabo C
    Br J Pharmacol; 2018 Jan; 175(2):232-245. PubMed ID: 28146604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.
    Kovacs K; Vaczy A; Fekete K; Kovari P; Atlasz T; Reglodi D; Gabriel R; Gallyas F; Sumegi B
    Invest Ophthalmol Vis Sci; 2019 Apr; 60(5):1478-1490. PubMed ID: 30973576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia.
    Teng F; Zhu L; Su J; Zhang X; Li N; Nie Z; Jin L
    Neurochem Res; 2016 Jul; 41(7):1516-26. PubMed ID: 26869042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
    J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.